These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 16144944

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM.
    Cancer Res; 2001 Jul 15; 61(14):5355-61. PubMed ID: 11454674
    [Abstract] [Full Text] [Related]

  • 3. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.
    Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK, Scott AM, Furnari FB.
    Clin Cancer Res; 2007 Mar 15; 13(6):1911-25. PubMed ID: 17363548
    [Abstract] [Full Text] [Related]

  • 4. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ, Huang HJ, Cavenee WK.
    Cancer Res; 2001 Jul 15; 61(14):5349-54. PubMed ID: 11454673
    [Abstract] [Full Text] [Related]

  • 5. MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor.
    Johns TG, McKay MJ, Cvrljevic AN, Gan HK, Taylor C, Xu H, Smyth FE, Scott AM.
    Int J Radiat Oncol Biol Phys; 2010 Oct 01; 78(2):572-8. PubMed ID: 20638193
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Bianco AR, Mendelsohn J, Tortora G.
    Clin Cancer Res; 2000 Sep 01; 6(9):3739-47. PubMed ID: 10999768
    [Abstract] [Full Text] [Related]

  • 8. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
    Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, Mendelsohn J, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2000 Nov 01; 6(11):4343-50. PubMed ID: 11106252
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation.
    Wang H, Shi B, Zhang Q, Jiang H, Hu S, Kong J, Yao M, Yang S, Li Z.
    FASEB J; 2012 Jan 01; 26(1):73-80. PubMed ID: 21917986
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
    Lammering G, Hewit TH, Holmes M, Valerie K, Hawkins W, Lin PS, Mikkelsen RB, Schmidt-Ullrich RK.
    Clin Cancer Res; 2004 Oct 01; 10(19):6732-43. PubMed ID: 15475464
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents.
    Knecht R, Peters S, Adunka O, Strebhardt K, Gstoettner W, Hambek M.
    Anticancer Res; 2003 Oct 01; 23(3B):2577-83. PubMed ID: 12894544
    [Abstract] [Full Text] [Related]

  • 14. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.
    Fan Z, Baselga J, Masui H, Mendelsohn J.
    Cancer Res; 1993 Oct 01; 53(19):4637-42. PubMed ID: 8402640
    [Abstract] [Full Text] [Related]

  • 15. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR.
    Clin Cancer Res; 2006 Sep 01; 12(17):5064-73. PubMed ID: 16951222
    [Abstract] [Full Text] [Related]

  • 16. The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR.
    Luwor RB, Zhu HJ, Walker F, Vitali AA, Perera RM, Burgess AW, Scott AM, Johns TG.
    Oncogene; 2004 Aug 12; 23(36):6095-104. PubMed ID: 15221011
    [Abstract] [Full Text] [Related]

  • 17. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
    Masui H, Moroyama T, Mendelsohn J.
    Cancer Res; 1986 Nov 12; 46(11):5592-8. PubMed ID: 3756906
    [Abstract] [Full Text] [Related]

  • 18. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action.
    Lammerts van Bueren JJ, Bleeker WK, Bøgh HO, Houtkamp M, Schuurman J, van de Winkel JG, Parren PW.
    Cancer Res; 2006 Aug 01; 66(15):7630-8. PubMed ID: 16885363
    [Abstract] [Full Text] [Related]

  • 19. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225.
    Ye D, Mendelsohn J, Fan Z.
    Oncogene; 1999 Jan 21; 18(3):731-8. PubMed ID: 9989823
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K, Brockmann MA, Eckerich C, Bohlen P, May C, Mangold U, Fillbrandt R, Westphal M.
    Clin Cancer Res; 2005 Jul 01; 11(13):4934-40. PubMed ID: 16000592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.